K Marek

Summary

Affiliation: Institute for Neurodegenerative Disorders
Country: USA

Publications

  1. ncbi Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease
    Kenneth Marek
    Department of Neurology, Institute for Neurogenerative Disorders, New Haven, Connecticut, USA
    Adv Neurol 91:183-91. 2003
  2. ncbi [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression
    K Marek
    Department of Neurology, Yale University School of Medicine, New Haven, CT, USA
    Neurology 57:2089-94. 2001
  3. ncbi Can we image premotor Parkinson disease?
    Kenneth Marek
    Institute for Neurodegenerative Disorders, New Haven, CT, USA
    Neurology 72:S21-6. 2009
  4. ncbi Do dopamine agonists or levodopa modify Parkinson's disease progression?
    K Marek
    The Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA
    Eur J Neurol 9:15-22. 2002
  5. ncbi Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies
    Kenneth Marek
    Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA
    Ann Neurol 53:S160-6; discussion S166-9. 2003
  6. ncbi Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression
    Kenneth Marek
    Institute for Neurodegenerative Disorders, New Haven, CT, USA
    Ann Neurol 64:S111-21. 2008
  7. ncbi The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease
    J Seibyl
    Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA
    Minerva Med 96:353-64. 2005
  8. ncbi The molecular basis of dopaminergic brain imaging in Parkinson's disease
    J Seibyl
    Institute for Neurodegenerative Disorders, Molecular NeuroImaging, LLC, New Haven, Connecticut 06510, USA
    Q J Nucl Med Mol Imaging 56:4-16. 2012
  9. ncbi Unique roles of SPET brain imaging in clinical and research studies. Lessons from Parkinson's disease research
    J Seibyl
    Institute for Neurodegenerative Disorders, 60 Temple Street, New Haven, CT 06510, USA
    Q J Nucl Med Mol Imaging 49:215-21. 2005
  10. ncbi Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease
    David K Simon
    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    BMC Med Genet 11:53. 2010

Collaborators

Detail Information

Publications21

  1. ncbi Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease
    Kenneth Marek
    Department of Neurology, Institute for Neurogenerative Disorders, New Haven, Connecticut, USA
    Adv Neurol 91:183-91. 2003
  2. ncbi [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression
    K Marek
    Department of Neurology, Yale University School of Medicine, New Haven, CT, USA
    Neurology 57:2089-94. 2001
    ..123I]beta-CIT and SPECT imaging of the dopamine transporter is a sensitive biomarker of PD onset and severity...
  3. ncbi Can we image premotor Parkinson disease?
    Kenneth Marek
    Institute for Neurodegenerative Disorders, New Haven, CT, USA
    Neurology 72:S21-6. 2009
    ....
  4. ncbi Do dopamine agonists or levodopa modify Parkinson's disease progression?
    K Marek
    The Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA
    Eur J Neurol 9:15-22. 2002
    ..These data highlight the need to compare imaging outcomes of dopamine neuronal loss with multiple meaningful clinical endpoints of disease progression in placebo controlled, larger and long-term studies...
  5. ncbi Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies
    Kenneth Marek
    Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA
    Ann Neurol 53:S160-6; discussion S166-9. 2003
  6. ncbi Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression
    Kenneth Marek
    Institute for Neurodegenerative Disorders, New Haven, CT, USA
    Ann Neurol 64:S111-21. 2008
    ....
  7. ncbi The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease
    J Seibyl
    Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA
    Minerva Med 96:353-64. 2005
    ....
  8. ncbi The molecular basis of dopaminergic brain imaging in Parkinson's disease
    J Seibyl
    Institute for Neurodegenerative Disorders, Molecular NeuroImaging, LLC, New Haven, Connecticut 06510, USA
    Q J Nucl Med Mol Imaging 56:4-16. 2012
    ..The interplay between other neurochemical brain systems and dopamine elucidates potential new targets for therapeutic intervention across the stages of the disease...
  9. ncbi Unique roles of SPET brain imaging in clinical and research studies. Lessons from Parkinson's disease research
    J Seibyl
    Institute for Neurodegenerative Disorders, 60 Temple Street, New Haven, CT 06510, USA
    Q J Nucl Med Mol Imaging 49:215-21. 2005
    ..Review of neuroimaging studies of PD provides a useful example of optimized approaches to clinical and research studies in neuropsychiatric disorders...
  10. ncbi Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease
    David K Simon
    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    BMC Med Genet 11:53. 2010
    ..We investigated the potential contribution of mtDNA variants or mutations to the risk of PD...
  11. ncbi Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa
    Kenneth Marek
    Institute for Neurodegenerative Disorders, New Haven, Connecticut 06510, USA
    Neurology 61:S43-8. 2003
  12. ncbi Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
    ..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
  13. ncbi Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  14. ncbi Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients
    I George Zubal
    Institute for Neurodegenerative Disorders, and Molecular Neuroimaging, LLC, New Haven, Connecticut 06510, USA
    J Nucl Med 48:857-64. 2007
    ....
  15. ncbi Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study
    Yili Shang
    Global Research and Development, Pfizer Inc, Groton, CT 06340, USA
    J Clin Psychopharmacol 27:71-5. 2007
    ....
  16. ncbi Levodopa and the progression of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    N Engl J Med 351:2498-508. 2004
    ..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease...
  17. ncbi The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study
    Alexandra Gaenslen
    Center of Neurology, Department of Neurodegeneration and Hertie Institute of Clinical Brain Research, University of Tubingen, Germany
    Lancet Neurol 7:417-24. 2008
    ..We aimed to determine the diagnostic value of TCS in the early stages of parkinsonian syndromes, when the clinical symptoms often do not enable a definite diagnosis to be made...
  18. ncbi Role of DAT-SPECT in the diagnostic work up of parkinsonism
    Christoph Scherfler
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mov Disord 22:1229-38. 2007
    ..This review addresses the value of DAT-SPECT in early differential diagnosis, and its potential as a screening tool for subjects at risk of developing PD as well as issues around the assessment of disease progression...
  19. ncbi Looking backward to move forward: early detection of neurodegenerative disorders
    Steven T DeKosky
    Department of Neurology and Alzheimer Disease Research Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Science 302:830-4. 2003
    ..Early detection of these slowly progressive diseases offers the promise of presymptomatic diagnosis and, ultimately, of disease-modifying medications for use early in disease and during the presymptomatic period...
  20. ncbi Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease
    Andrew Siderowf
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 22:2249-55. 2007
    ..Further research is warranted to determine whether a history of lower caffeine consumption confers additional risk for the development of PD in hyposmic relatives of PD patients...